COPE
Volume 7, Issue 2 (May 2019)                   Res Mol Med (RMM) 2019, 7(2): 0-0 | Back to browse issues page

XML Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Namazi F, Hadi N, Parnian F, Moghimi M. Evaluation of IL-2 and IL-7 Expression in Patients with Prostate Cancer . Res Mol Med (RMM). 2019; 7 (2)
URL: http://rmm.mazums.ac.ir/article-1-321-en.html
Abstract:   (162 Views)
Background/aim: Prostate cancer is a biologically heterogeneous disease which has become the fifth leading cause of death from cancer in men worldwide. Interleukins (IL) represent essential inflammation mediators. IL-2 and IL-7 play major roles in regulating cancer-immune system interactions. So, the aim of this investigation was to evaluate the expression level of IL-2 and IL-7 in patients with prostate cancer and controls.
Materials and methods: In this case-control study, expression of IL-2 and IL-7 was examined in peripheral blood of 40 patients with prostate cancer and 40 controls using reverse transcription quantitative PCR (RT-qPCR).
Results: Our findings showed that IL-7 has highly elevated expression in patients with prostate cancer compared to healthy subjects. In contrast, there was no statistically significant difference in the expression of the IL-2 between patients and controls.
Conclusions: Based on the results IL-7 may be a prospective biomarker or as a molecular target in designing new prostate cancer control strategies. However, the findings of this investigation revealed no association between IL-2 expression and prostate cancer. However, more studies should be included to appraise the exact relevance of this gene to prostate cancer.
 
     
Type of Study: Research | Subject: Genetic
Received: 2019/07/23

Add your comments about this article : Your username or Email:
CAPTCHA

Send email to the article author


© 2019 All Rights Reserved | Research in Molecular Medicine

Designed & Developed by : Yektaweb